Polyester nanomedicines for visceral leishmaniasis treatment

References

• 1. Eaton P, Bittencourt CR, Costa Silva V et al. Anti-leishmanial activity of the antimicrobial peptide DRS 01 observed in Leishmania infantum (syn. Leishmania chagasi) cells. Nanomedicine 10(2), 483–490 (2014).
  Medline CASGoogle Scholar
• 2. Alemayehu B, Alemayehu M. Leishmaniasis: a review on parasite, vector and reservoir host. Heal. Sci. J. 11(4), 519 (2017).
  Google Scholar
• 3. Jain K, Verma AK, Mishra PR, Jain NK. Characterization and evaluation of amphotericin B loaded MDP conjugated poly(propylene imine) dendrimers. Nanomedicine 11(3), 705–713 (2015).
  Medline CASGoogle Scholar
• 4. Liu Q, Zou J, Chen Z, He W, Wu W. Current research trends of nanomedicines. Acta Pharm. Sin. B doi: 10.1016/j.apsb.2023.05.018 (2023) (Online).
  Google Scholar
• 5. Gutiérrez V, Seabra AB, Reguera RM, Khandare J, Calderón M. New approaches from nanomedicine for treating leishmaniasis. Chem. Soc. Rev. 45(1), 152–168 (2015).
  Google Scholar
• 6. Karlsson J, Vaughan HJ, Green JJ. Biodegradable polymeric nanoparticles for therapeutic cancer treatments. Ann. Rev. Chem. Biomol. Eng. 9, 105 (2018).
  Medline CASGoogle Scholar
• 7. Tang H, Zhao W, Yu J, Li Y, Zhao C. Recent development of pH-responsive polymers for cancer nanomedicine. Molecules 24(1), 4 (2018).
  MedlineGoogle Scholar
• 8. Kumar R, Gupta PK, Pandit S et al. Synthesis and characterization of biocompatible bimetallic-semi-aromatic polyester hybrid nanocomposite. Colloids Surf. A Physicochem. Eng. Asp. 633(1), 127845 (2022).
  CASGoogle Scholar
• 9. Chauhan S, Al-Dayan N, Kumar R et al. Synthesis and characterization of novel bimetallic-semi-aromatic polyester nanocomposite for possible biomedical use. Mater. Lett. 306(1), 130943 (2022).
  CASGoogle Scholar
• 10. Bigaj-Józefowska MJ, Grześkowiak BF. Polymeric nanoparticles wrapped in biological membranes for targeted anticancer treatment. Eur. Polym. J. 176(8), 111427 (2022).
  CASGoogle Scholar
• 11. Katebi A, Varshochian R, Riazi-Rad F, Ganjalikhani-Hakemi M, Ajdary S. Combinatorial delivery of antigen and TLR agonists via PLGA nanoparticles modulates Leishmania major-infected-macrophages activation. Biomed. Pharmacother. 137(5), 111276 (2021).
  Medline CASGoogle Scholar
• 12. Puig-Rigall J, Fernández-Rubio C, González-Benito J et al. Structural characterization by scattering and spectroscopic methods and biological evaluation of polymeric micelles of poloxamines and TPGS as nanocarriers for miltefosine delivery. Int. J. Pharm. 578(3), 119057 (2020).
  Medline CASGoogle Scholar
• 13. Saqib M, Shabbir Ali Bhatti A, Ahmad NM et al. Amphotericin B loaded polymeric nanoparticles for treatment of Leishmania infections. Nanomaterials (Basel) 10(6), 1152 (2020).
  Medline CASGoogle Scholar
• 14. Tambe S, Kumar R, Amin P et al. Current aspects of organoid technology for biomaterial toxicity analysis. Future Med. Chem. 15(7), 579–582 (2023).
  Medline CASGoogle Scholar
• 15. Meireles PW, de Souza DPB, Rezende MG et al. Nanoparticles loaded with a new thiourea derivative: development and in vitro evaluation against Leishmania amazonensis. Curr. Drug Deliv. 17(8), 694–702 (2020).
  Medline CASGoogle Scholar
• 16. Valle IV, Machado ME, Araújo CDCB et al. Oral pentamidine-loaded poly(d,l-lactic-co-glycolic) acid nanoparticles: an alternative approach for leishmaniasis treatment. Nanotechnology 30, 455102 (2019).
  Medline CASGoogle Scholar
• 17. Afzal I, Sarwar HS, Sohail MF et al. Mannosylated thiolated paromomycin-loaded PLGA nanoparticles for the oral therapy of visceral leishmaniasis. Nanomedicine (Lond.) 14(4), 387–406 (2019).
  CASGoogle Scholar
• 18. Abamor ES. Antileishmanial activities of caffeic acid phenethyl ester loaded PLGA nanoparticles against Leishmania infantum promastigotes and amastigotes in vitro. Asian Pac. J. Trop. Med. 10(1), 25–34 (2017).
  Medline CASGoogle Scholar